HALOZYME THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate
HALOZYME THERAPEUTICS, INC. (HALO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 66.80% for the 3-month period ending 2015-06-30, per its 10-Q filed 2015-08-10.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2015-08-10
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2015-06-30 was 66.80%, a 6.05% decline year-over-year.
- HALOZYME THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2014-06-30 was 71.10%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 month |
|---|---|---|
| 2015-06-30 | 66.80% 10-Q · filed 2015-08-10 | 66.70% 10-Q · filed 2015-08-10 |
| 2014-06-30 | 71.10% 10-Q · filed 2015-08-10 | 71.00% 10-Q · filed 2015-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |